Open AccessBlocking stanniocalcin 2 reduces sunitinib resistance in clear cell renal cell carcinoma
Author(s) -
Zhenqian Qin,
Kongdong Li,
Hezhen Chu,
Xuefeng Yuan,
Haifeng Shi,
Jie Gu,
Yimin Xie
Publication year - 2022
Publication title -
neoplasma
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.628
H-Index - 50
eISSN - 1338-4317
pISSN - 0028-2685
DOI - 10.4149/neo_2021_210823n1206
Subject(s) - sunitinib , clear cell renal cell carcinoma , renal cell carcinoma , cancer research , cell , antibody , cell growth , immunotherapy , biology , secretion , medicine , immunology , endocrinology , immune system , genetics
Stanniocalcin 2 (STC2) has been identified as a prognostic marker in renal cell carcinoma. However, the role of STC2 in renal cell carcinoma is still unclear. In this study, we investigated the relationship between high expression of STC2 and sunitinib resistance in cells and the underlying mechanism. Through GEPIA platform analysis based on TCGA database, it showed that the expression of STC2 in kidney renal clear cell carcinoma (KIRC) was significantly higher than that in the normal population. Real-time quantitative PCR and western blotting detected significantly higher expression levels of STC2 in clear cell renal cell carcinoma (ccRCC) cells than that in normal renal cells. Enzyme-linked immunosorbent assay (ELISA) determined whether there is a high secretion of STC2 in ccRCC cells. The sunitinib resistance could be significantly reduced by STC2 neutralizing antibody but aggravated by the addition of recombinant human STC2 in ccRCC cells. Sunitinib suppressed STC2 expression and secretion, destroyed lysosomal acidic pH, and accumulated in the cells. However, STC2 neutralizing antibody can reduce the accumulation of sunitinib in cells to improve the inhibitory efficiency of sunitinib on cell proliferation. This study suggested STC2 could serve as a potential novel target for the treatment of ccRCC, anti-STC2 antibody might be an option of immunotherapy in the future.